Constitutive JunB expression, associated with the JAK2 V617F mutation, stimulates proliferation of the erythroid lineage

[1]  W. Vainchenker,et al.  Selective reduction of JAK2V617F-dependent cell growth by siRNA/shRNA and its reversal by cytokines. , 2009, Blood.

[2]  R. Tiedt,et al.  Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. , 2007, Blood.

[3]  L. Kenner,et al.  The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling. , 2007, Blood.

[4]  Francesco Mannelli,et al.  Molecular Profiling of CD34+ Cells in Idiopathic Myelofibrosis Identifies a Set of Disease‐Associated Genes and Reveals the Clinical Significance of Wilms' Tumor Gene 1 (WT1) , 2007, Stem cells.

[5]  F. Bertucci,et al.  Oncogenic kinases of myeloproliferative disorders induce both protein synthesis and G1 activators , 2006, Leukemia.

[6]  W. Vainchenker,et al.  JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. , 2006, Blood.

[7]  D. Neuberg,et al.  Activated Jak2 with the V617F Point Mutation Promotes G1/S Phase Transition* , 2006, Journal of Biological Chemistry.

[8]  R. Levine,et al.  Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. , 2006, Blood.

[9]  C. Peschle,et al.  Increased death receptor resistance and FLIPshort expression in polycythemia vera erythroid precursor cells. , 2006, Blood.

[10]  H. Drexler,et al.  JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders , 2006, Leukemia.

[11]  H. Lodish,et al.  Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[12]  W. Vainchenker,et al.  Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells. , 2005, Blood.

[13]  M. Cazzola,et al.  Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. , 2005, Blood.

[14]  W. Vainchenker,et al.  RGS16 is a negative regulator of SDF-1-CXCR4 signaling in megakaryocytes. , 2005, Blood.

[15]  D. Oscier,et al.  Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. , 2005, Blood.

[16]  Qingshan Li,et al.  Identification of an Acquired JAK2 Mutation in Polycythemia Vera* , 2005, Journal of Biological Chemistry.

[17]  Stefan N Constantinescu,et al.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. , 2005, Nature.

[18]  W. Hofmann,et al.  Detection of Aberrant Gene Expression in CD34+ Hematopoietic Stem Cells from Patients with Agnogenic Myeloid Metaplasia Using Oligonucleotide Microarrays , 2005, Stem cells.

[19]  Mario Cazzola,et al.  A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.

[20]  T. Maiwald,et al.  Gene expression profiling in polycythaemia vera: overexpression of transcription factor NF‐E2 , 2005, British journal of haematology.

[21]  Sandra A. Moore,et al.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.

[22]  P. Campbell,et al.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.

[23]  I. Weissman,et al.  JunB Deficiency Leads to a Myeloproliferative Disorder Arising from Hematopoietic Stem Cells , 2004, Cell.

[24]  E. Wagner,et al.  Mice lacking JunB are osteopenic due to cell-autonomous osteoblast and osteoclast defects , 2004, The Journal of cell biology.

[25]  W. Vainchenker,et al.  Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera. , 2004, Experimental hematology.

[26]  E. Wagner,et al.  JunB inhibits proliferation and transformation in B-lymphoid cells. , 2003, Blood.

[27]  C. Langford,et al.  Gene expression profiling in polycythemia vera using cDNA microarray technology. , 2003, Cancer research.

[28]  A. Kolbus,et al.  Cell Cycle Promoting Activity of JunB through Cyclin A Activation* , 2002, The Journal of Biological Chemistry.

[29]  F. Speleman,et al.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes , 2002, Genome Biology.

[30]  M. Karin,et al.  AP-1 as a regulator of cell life and death , 2002, Nature Cell Biology.

[31]  A. Wickrema,et al.  Role of JunB in Erythroid Differentiation* , 2002, The Journal of Biological Chemistry.

[32]  E. Wagner,et al.  JunB can substitute for Jun in mouse development and cell proliferation , 2002, Nature Genetics.

[33]  M. Karin,et al.  AP-1 in cell proliferation and survival , 2001, Oncogene.

[34]  E. Wagner,et al.  Chronic Myeloid Leukemia with Increased Granulocyte Progenitors in Mice Lacking JunB Expression in the Myeloid Lineage , 2001, Cell.

[35]  N. Fusenig,et al.  c-Jun and JunB Antagonistically Control Cytokine-Regulated Mesenchymal–Epidermal Interaction in Skin , 2000, Cell.

[36]  Lee Kc.  Derivation of a new hematopoietic cell line with endothelial features from a patient with transformed myeloproliferative syndrome. A case report. , 2000 .

[37]  E. Wagner,et al.  JunB suppresses cell proliferation by transcriptional activation of p16INK4a expression , 2000, The EMBO journal.

[38]  E. Bossy‐Wetzel,et al.  Cell cycle‐dependent variations in c‐Jun and JunB phosphorylation: a role in the control of cyclin D1 expression , 2000, The EMBO journal.

[39]  M. Birrer,et al.  AP1 Regulation of Proliferation and Initiation of Apoptosis in Erythropoietin-Dependent Erythroid Cells , 1998, Molecular and Cellular Biology.

[40]  C. Richard,et al.  Expression of Bcl-x in erythroid precursors from patients with polycythemia vera. , 1998, The New England journal of medicine.

[41]  C. Hanson,et al.  Both the Polycythemia- and Anemia-Inducing Strains of Friend Spleen Focus-Forming Virus Induce Constitutive Activation of the Raf-1/Mitogen-Activated Protein Kinase Signal Transduction Pathway , 1998, Journal of Virology.

[42]  J. Claverie,et al.  The significance of digital gene expression profiles. , 1997, Genome research.

[43]  E. Zandi,et al.  AP-1 function and regulation. , 1997, Current opinion in cell biology.

[44]  M. Karin.  The regulation of AP-1 activity by mitogen-activated protein kinases. , 1996, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[45]  A. Kraft,et al.  Signal Transduction by a CD16/CD7/Jak2 Fusion Protein (*) , 1995, The Journal of Biological Chemistry.

[46]  Yuh Cheng Yang,et al.  Activation of junB and c‐myc primary response genes by interleukin 9 in a human factor‐dependent cell line , 1995, Journal of cellular physiology.

[47]  L. Sanders,et al.  Transcriptional regulatory elements downstream of the JunB gene. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[48]  H. Saito,et al.  Induction of junB expression, but not c-jun, by granulocyte colony-stimulating factor or macrophage colony-stimulating factor in the proliferative response of human myeloid leukemia cells. , 1992, The Journal of clinical investigation.

[49]  D. Liebermann,et al.  Dissection of the immediate early response of myeloid leukemia cells to terminal differentiation and growth inhibitory stimuli. , 1990, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[50]  S. Ruscetti,et al.  Friend spleen focus-forming virus induces factor independence in an erythropoietin-dependent erythroleukemia cell line , 1990, Journal of virology.

[51]  L. Lau,et al.  A gene activated by growth factors is related to the oncogene v-jun. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[52]  K. Takenaka,et al.  Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F , 2008, Leukemia.